trending Market Intelligence /marketintelligence/en/news-insights/trending/gHon_BPOIkT_OCvAV5UpJA2 content esgSubNav
In This List

Prescient puts cancer drug trial on hold after patient death

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Prescient puts cancer drug trial on hold after patient death

Prescient Therapeutics Ltd. placed the phase 1b breast cancer trial of its lead drug PTX-200 on hold after reporting a fatality.

The trial, which enrolled 29 patients, was evaluating PTX-200 in combination with chemotherapy drug paclitaxel. The Australian company said the patient, suffering from stage 4 metastatic triple negative breast cancer, experienced hepatic or liver failure during treatment with the medication.

The principal investigator of the trial believes the death could be related to PTX-200, paclitaxel or pioglitazone, a diabetes drug.

Prescient said it temporarily paused recruitment to all PTX-200 trials to further investigate the death and notified the U.S. Food and Drug Administration, which put the trial on clinical hold.

The patient death would appear as a blow to the company, given that PTX-200 was scheduled to move into phase 2 study.